Form 4: 4D Molecular Therapeutics CEO David Kirn Awarded Stock Options

4D Molecular Therapeutics CEO David Kirn was granted stock options to purchase 267,500 shares of common stock on March 6, 2025.

Summary

• David Kirn, CEO of 4D Molecular Therapeutics, was granted stock options on March 6, 2025.
• The options allow him to purchase 267,500 shares of the company's common stock at an exercise price of $4.14 per share.
• The options vest monthly over four years, starting March 6, 2025, with full vesting on the fourth anniversary, contingent upon continued service to the company.
• The options expire on March 5, 2035.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of a stock option grant, which is generally viewed as a positive incentive for management. The sentiment is neutral to slightly positive.

Positives

• The stock option grant aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules of four years with monthly vesting are typical to ensure long-term commitment.
• The size of the grant (267,500 shares) would need to be compared to grants given to CEOs of similarly sized biotech companies to assess its relative value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO.
• Employees may see it as a sign of confidence in the company's future.

Key Dates